Company / Return on Assets (ROA)
NewAmsterdam Pharma Co N.V. Return on Assets (ROA) History
FY2022-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Assets (ROA)
-26.5%
FY2025
5-year range
-51.0% / -4.7%
FY2022-FY2025
Trend
+5.2%
vs FY2024
Sector context
#125 of 213
Health Care
What the data says
At -26.5%, NewAmsterdam Pharma Co N.V.'s return on assets (roa) ranks #125 of 213 in the Health Care sector. Improved from -51.0% to -26.5% over the past 2 years.
Based on SEC 10-K filings.
-26.5% in FY2025 with a 3-year CAGR of -21.8%.
Improved from -51.0% to -26.5% over the past 2 years.
Health Care sector context is included.
Return on Assets (ROA) over time
Growth rates
- 3-Year Change
- -21.8pp
- 5-Year Change
- -
- 10-Year Change
- -
Sector benchmark
#125 of 213 in Health CareTop 59% of 213This company -26.5% Sector average -24.1%
▼
-9.7% below sector average
Key checks
Key Insights
- In FY2025, return on assets (roa) increased 5.2% year-over-year.
- Currently 2.3pp below the Health Care sector average.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 3.01 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Assets (ROA)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -26.5% | +5.2% |
| FY2024 | -27.9% | +45.2% |
| FY2023 | -51.0% | -977.8% |
| FY2022 | -4.7% | - |
| FY2021 | - | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026